Sarepta Therapeutics Valuation
| S1RP34 Stock | BRL 38.32 0.04 0.10% |
At this time, the company appears to be overvalued. Sarepta Therapeutics has a current Real Value of R$31.7 per share. The regular price of the company is R$38.32. Our model measures the value of Sarepta Therapeutics from inspecting the company fundamentals such as Shares Outstanding of 1.76 B, operating margin of (0.61) %, and Return On Equity of -1.59 as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Sarepta Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Sarepta Therapeutics is based on 3 months time horizon. Increasing Sarepta Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sarepta Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sarepta Stock. However, Sarepta Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 38.32 | Real 31.7 | Hype 38.32 | Naive 39.84 |
The real value of Sarepta Stock, also known as its intrinsic value, is the underlying worth of Sarepta Therapeutics Company, which is reflected in its stock price. It is based on Sarepta Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Sarepta Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Sarepta Therapeutics helps investors to forecast how Sarepta stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sarepta Therapeutics more accurately as focusing exclusively on Sarepta Therapeutics' fundamentals will not take into account other important factors: Sarepta Therapeutics Total Value Analysis
Sarepta Therapeutics is at this time projected to have takeover price of 56.41 B with market capitalization of 58.46 B, debt of 1.1 B, and cash on hands of 1.74 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Sarepta Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
56.41 B | 58.46 B | 1.1 B | 1.74 B |
Sarepta Therapeutics Investor Information
The company recorded a loss per share of 22.24. Sarepta Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Sarepta Therapeutics' liquidity, profitability, solvency, and operating efficiency, Sarepta Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Sarepta Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sarepta Therapeutics has an asset utilization ratio of 22.3 percent. This suggests that the Company is making R$0.22 for each dollar of assets. An increasing asset utilization means that Sarepta Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Sarepta Therapeutics Profitability Analysis
The company reported the revenue of 701.89 M. Net Loss for the year was (418.78 M) with loss before overhead, payroll, taxes, and interest of (165.84 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Sarepta Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Sarepta Therapeutics and how it compares across the competition.
About Sarepta Therapeutics Valuation
The stock valuation mechanism determines Sarepta Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Sarepta Therapeutics. We calculate exposure to Sarepta Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sarepta Therapeutics's related companies.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. SAREPTA THERDRN operates under Biotechnology classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 866 people.
8 Steps to conduct Sarepta Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Sarepta Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Sarepta Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Sarepta Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Sarepta Therapeutics' revenue streams: Identify Sarepta Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Sarepta Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Sarepta Therapeutics' growth potential: Evaluate Sarepta Therapeutics' management, business model, and growth potential.
- Determine Sarepta Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Sarepta Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Sarepta Stock analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |